OBJECTIVES: To carry out an economic evaluation of the use of botulinum toxin type A (XEOMEEN), also known as incobotulinum toxin type A (INCO), in the treatment of adult patients with spasticity from the perspective of the "Instituto Mexicano del Seguro Social" (IMSS) and the “Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado” (ISSSTE).

METHODS: A systematic review (SR) of the literature was performed to evaluate the efficacy and safety of INCO, in comparison with onabotulinum toxin type A (ONA) and abobotulinum toxin type A (ABO), in adult patients with spasticity. The evaluated outcomes were Disability Assessment Scale (DAS), reduction in hypertonicity and adverse event (AE) rate. With the information obtained, a complete economic evaluation of the cost minimization analysis (AMC) type was carried out. The AMC compared the direct medical costs associated with the use of INCO and its comparators (ONA and ABO), contemplating a time horizon of 1 year, as it is the evaluation of a chronic condition.

RESULTS: The clinical evidence obtained in the SR indicates that the safety and efficacy of INCO are equivalent to those obtained with ONA and ABO for DAS, reduction in hypertonicity and AE rate in the treatment of adult patients with spasticity. INCO is a cost-saving option and, in monetary terms, it represents an average annual savings for the IMSS of $8,753.42 MXN and $10,495.73 MXN for the ISSSTE, per patient under treatment, which in percentage terms translates into 35.85% and 40.13% respectively.

CONCLUSIONS: INCO is equivalent in safety and efficacy in the treatment of adult patients with spasticity, compared to ONA and ABO. Therefore, the botulinum toxin type A (XEOMEEN) is a cost-saving option for the IMSS and ISSSTE.